What the Virtual Lab nanobody study demonstrated
Researchers combined AI agents, specialist software and experimental validation to design 92 candidates.
Originally posted · Published here · 1 source · Resume reading
The Virtual Lab study described an AI-human research collaboration that designed 92 new SARS-CoV-2 nanobodies. The paper appeared in Nature in July 2025 [1].
How the collaboration worked
A language-model principal investigator guided specialist language-model agents through research meetings. A human researcher supplied high-level feedback. The resulting design pipeline used ESM, AlphaFold-Multimer and Rosetta [1].
The work therefore combined several components: discussion and planning by language models, specialist computational tools and human direction. Calling it simply an AI that invented a medicine hides those dependencies.
Designs still needed experiments
The authors reported experimental validation and promising binding profiles across virus variants [1]. A designed candidate and a measured binding result are different stages of evidence. Neither, by itself, establishes a treatment's clinical safety or effectiveness.
Our caption emphasized speed. The more useful engineering lesson is the division of work and the presence of an external check. The language models did not get to declare success solely by reviewing their own answers.
Read this as a research demonstration of a coordinated workflow. It does not establish that a general-purpose chatbot can independently produce a usable medical treatment.
Keep this guide
Filed under AI agents
Sources
- Nature: Virtual Lab research papernature.com
Next in this stack
Keyword LOOP
Five rules for building an AI agent that works
Keyword STARTER
Write skill metadata an agent can recognize
Keyword SIMPLEFIRST
Choose an AI workflow before building an agent